Search

Displaying results 4861 - 4870 of 10000 in total
  1. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  2. Drug

    Setiptiline

    go.drugbank.com/drugs/DB09304
    Experimental

    In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.

  3. Drug

    Zinc picolinate

    go.drugbank.com/drugs/DB11175
    Investigational

    It is available as OTC dietary supplements as a source of zinc to treat and prevent zinc deficiency. The absorption of zinc after oral administration of zinc picolinate is shown to be effective.

  4. Drug

    7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

    go.drugbank.com/drugs/DB08550
    Experimental

    Potent reversible inhibitor of phenylethanolamine N-methyltransferase.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Marimastat

    go.drugbank.com/drugs/DB00786
    Investigational

    Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. … As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.

  6. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

  7. Drug

    Beraprost

    go.drugbank.com/drugs/DB05229
    Investigational

    Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

  8. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.

  9. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion. … UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.

  10. Drug

    (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime

    go.drugbank.com/drugs/DB08553
    Experimental

    (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. … These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.

    Synonyms: (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime